Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 26;26(7):3008.
doi: 10.3390/ijms26073008.

Association of Complement Proteins with C Reactive Protein in Non-Obese Women with and Without Polycystic Ovary Syndrome

Affiliations

Association of Complement Proteins with C Reactive Protein in Non-Obese Women with and Without Polycystic Ovary Syndrome

Alexandra E Butler et al. Int J Mol Sci. .

Abstract

Complement proteins are increased in polycystic ovary syndrome (PCOS), as are markers of inflammation, such as the C-reactive protein (CRP); however, both may be increased in obesity. We hypothesised that body mass index (BMI)-driven CRP would comparably associate with an increase in complement proteins when obesity was accounted for in non-obese women with and without PCOS. In a non-obese, non-insulin-resistant population without inflammation (24 with PCOS and 24 control women), plasma CRP was measured by immunoassay. Slow Off-rate Modified Aptamer (SOMA)-scan plasma proteomic analysis of the classical, lectin, and alternative pathway complement proteins was undertaken. BMI, insulin resistance, and CRP did not differ (p < 0.05) between the cohorts. The alternative pathway of the complement protein system was overexpressed in PCOS (p < 0.05). CRP correlated positively (p < 0.05) with alternate pathway parameters in women with and without PCOS for C3a, iC3b, Factor B, Factor H, and Factor I; in PCOS alone for C3, C3adesArg, and C3d; and in women without PCOS, for properdin. CRP did not correlate with lectin pathway C2 or MBL (p > 0.05). CRP correlated positively (p < 0.05) with C4 of the classical pathways in women with PCOS alone. Hyperandrogenemia did not correlate with CRP or complement in non-obese PCOS. BMI correlated positively with C3, C3adesArg, C3a, iC3b, Factor B, Factor H, and properdin: classical pathway proteins; C1q, C4, C5 and C5a in PCOS women; BMI only correlated negatively with C1q in non-PCOS women. Upregulation of complement proteins occur in non-obese PCOS, and CRP is positively associated with complement protein changes in both women with and without PCOS. This indicates that BMI induces changes in CRP that lead to changes in the complement pathways, particularly the alternate pathway, with increases in CRP (though still within the reference laboratory normal range) leading to upregulation of complement proteins in PCOS. This suggests an enhanced set point for CRP-induced complement protein dysregulation in PCOS.

Keywords: BMI; C-reactive protein (CRP); complement factors; inflammation; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
A schematic illustrating the initiating proteins of the classical (left panel), lectin (middle panel), and alternative (right panel) complement protein cascades. The green arrows in the illustration indicate the enzymatic activity or positive regulation, whereas the red arrows indicate the inhibition of pathways. The proteins that showed positive correlations with the C-reactive protein (CRP) were indicated by (+) signs. Cl, control; PCOS, polycystic ovary syndrome; C1–C9, complement protein component 1–9; MBL, Mannose-binding Lectin; MASP, Mannose-associated serine protease; DAF, Decay-accelerating factor; CFHR5, Complement factor H-related protein 5. Illustration was created using Biorender.com (accessed on 8 February 2025).
Figure 2
Figure 2
Correlations of BMI with CRP (A); testosterone with CRP (B); testosterone and BMI (C). There was a positive correlation of BMI with CRP in the PCOS cohort only, whilst no correlation was seen for testosterone with CRP or testosterone with BMI in either cohort.
Figure 3
Figure 3
Correlations of complement proteins with CRP in women with non-obese PCOS (n = 24) and weight matched controls (n = 24): C3 (A); C3a (B); C3adesArg (C); C3d (D); iC3b (E); C4 (F); Factor B (G); Factor H (H); Factor I (I); and Properdin (J). Relative Fluorescent Units (RFU).

References

    1. Sathyapalan T., Atkin S.L. Recent advances in cardiovascular aspects of polycystic ovary syndrome. Eur. J. Endocrinol. Eur. Fed. Endocr. Soc. 2012;166:575–583. doi: 10.1530/EJE-11-0755. - DOI - PubMed
    1. Carter A.M. Complement activation: An emerging player in the pathogenesis of cardiovascular disease. Scientifica. 2012;2012:402783. doi: 10.6064/2012/402783. - DOI - PMC - PubMed
    1. Sathyapalan T., Shepherd J., Coady A.M., Kilpatrick E.S., Atkin S.L. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2012;97:3951–3955. - PubMed
    1. Bannigida D.M., Nayak B.S., Vijayaraghavan R. Insulin resistance and oxidative marker in women with PCOS. Arch. Physiol. Biochem. 2020;126:183–186. - PubMed
    1. Niinuma S.A., Lubbad L., Lubbad W., Moin A.S.M., Butler A.E. The Role of Heat Shock Proteins in the Pathogenesis of Polycystic Ovarian Syndrome: A Review of the Literature. Int. J. Mol. Sci. 2023;24:1838. doi: 10.3390/ijms24031838. - DOI - PMC - PubMed